{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:48:18Z","timestamp":1764604098239,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer is among the most lethal gynecologic malignancies, with a high proportion of patients diagnosed at advanced stages, leading to poor survival outcomes. Axillary lymph node metastasis from ovarian cancer is extremely rare and the mechanism is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive set of clinical and gynecologic oncology assessments were performed, including ultrasound, mammography, MRI, transvaginal ultrasound, and tissue staining. To unravel the carcinogenesis, the next-generation sequencing (NGS) was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Conventional examinations and imaging suggested the presence of both occult breast cancer and ovarian cancer. However, immunohistochemical staining confirmed the diagnosis of high-grade serous ovarian carcinoma. Further analysis of NGS identified two novel missense mutations, D326E in BTK (Bruton\u2019s tyrosine kinase) at SH2 domain and D251E in EPHA5 (EPH receptor A5), along with other known cancer- associated mutations. These mutations, particularly the novel missense mutations, may lead to metastasis to the axillary lymph nodes and drug resistance. Therefore, based on these findings, the chemotherapy regimen was adjusted accordingly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first report on the panorama gene profile of ovarian cancer metastasis to axillary lymph node and we found two novel mutations (BTK pD326E and EPHA5 pD251E). This study unraveled the potential mechanism of genetic mutation for tumor metabolism, drug resistance, and metastasis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1548102","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:16:00Z","timestamp":1737702960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.016","article-title":"Ovarian cancer metastasis: Looking beyond the surface","volume":"42","author":"Bayraktar","year":"2024","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103640","DOI":"10.1016\/j.amsu.2022.103640","article-title":"Recurrent ovarian cancer presenting with isolated axillary lymph node metastasis: A rare case report","volume":"77","author":"Phung","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.925089","article-title":"Breast and axillary lymph node metastasis from ovarian cancer: A case report","volume":"21","author":"Longo","year":"2020","journal-title":"Am J Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2054","article-title":"Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","volume":"7","author":"Fackenthal","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.v52.10","article-title":"A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis","volume":"52","author":"Eifert","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0668-3","article-title":"BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis","volume":"38","author":"Das","year":"2019","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220801101706","article-title":"Next-generation bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- recent developments and perspectives","volume":"22","author":"Das","year":"2022","journal-title":"Curr Top Med Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell Malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2009.04.009","article-title":"Synapse development and plasticity: roles of ephrin\/Eph receptor signaling","volume":"19","author":"Lai","year":"2009","journal-title":"Curr Opin Neurobiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1521","article-title":"Eph receptor tyrosine kinases in tumor immunity","volume":"76","author":"Shiuan","year":"2016","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0207-6","article-title":"EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma","volume":"28","author":"Huang","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101566","DOI":"10.1016\/j.mcp.2020.101566","article-title":"EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion","volume":"52","author":"Zhang","year":"2020","journal-title":"Mol Cell Probes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.06.031","article-title":"Substitution of aspartic acid with glutamic acid increases the unfolding transition temperature of a protein","volume":"320","author":"Lee","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41467-020-16128-5","article-title":"Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms","volume":"11","author":"Duarte","year":"2020","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01473","article-title":"Emerging roles for eph receptors and ephrin ligands in immunity","volume":"10","author":"Darling","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13048-016-0292-1","article-title":"EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma","volume":"9","author":"Chen","year":"2016","journal-title":"J Ovarian Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and Malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imm.v164.4","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell Malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.130198197","article-title":"Regulation of oxidative stress-induced calcium release by phosphatidylinositol 3-kinase and Bruton's tyrosine kinase in B cells","volume":"97","author":"Qin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.12.001","article-title":"EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation","volume":"48","author":"Nguyen","year":"2017","journal-title":"Exp Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5114\/pjp.2022.120097","article-title":"Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients","volume":"73","author":"Abouhashem","year":"2022","journal-title":"Pol J Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0954-07.2007","article-title":"Multiple effects of ephrin-A5 on cortical neurons are mediated by SRC family kinases","volume":"27","author":"Zimmer","year":"2007","journal-title":"J Neurosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2620","article-title":"BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors","volume":"83","author":"Petrelli","year":"2023","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:16:06Z","timestamp":1737702966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1548102"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1548102","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1548102"}}